NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis $26.39 -0.64 (-2.37%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$25.50▼$27.3950-Day Range$15.46▼$27.9952-Week Range$11.39▼$28.83Volume1.47 million shsAverage Volume903,061 shsMarket Capitalization$2.14 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verona Pharma alerts: Email Address Verona Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.4% Upside$36.00 Price TargetShort InterestBearish13.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.07) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector668th out of 910 stocksPharmaceutical Preparations Industry309th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Verona Pharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.17% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Verona Pharma has recently increased by 21.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRNA. Previous Next 1.8 News and Social Media Coverage News SentimentVerona Pharma has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Verona Pharma this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for VRNA on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($2.07) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -34.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -34.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 12.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verona Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Verona Pharma Stock (NASDAQ:VRNA)Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More VRNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRNA Stock News HeadlinesSeptember 5 at 2:00 AM | globenewswire.comVerona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024September 1, 2024 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7%September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 31, 2024 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) Short Interest UpdateAugust 28, 2024 | uk.finance.yahoo.comVerona Pharma PLC (I9SA.SG)August 15, 2024 | finance.yahoo.comInsider Sale: CFO Mark Hahn Sells 400,000 Shares of Verona Pharma PLC (VRNA)August 14, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Higher in Wednesday TradingAugust 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verona Pharma: Breakthrough COPD Treatment and Strategic Market PositioningSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 9, 2024 | finance.yahoo.comIs Verona Pharma plc (VRNA) a Good Addition to Your Portfolio Now?August 8, 2024 | globenewswire.comVerona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 3, 2024 | finance.yahoo.comVerona Pharma plc's (NASDAQ:VRNA) Path To ProfitabilityJuly 30, 2024 | msn.comTop 3 Health Care Stocks You May Want To Dump This QuarterJuly 30, 2024 | globenewswire.comVerona Pharma to Present at 44th Annual Canaccord Growth ConferenceJuly 25, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Slightly in Thursday TradingJuly 25, 2024 | globenewswire.comVerona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateJuly 19, 2024 | uk.finance.yahoo.comVerona Pharma PLC (I9SA.DU)June 30, 2024 | seekingalpha.comVerona Pharma Is Launching Ohtuvayre, Although There Will Be CompetitionSee More Headlines Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$38.00 Low Stock Price Target$33.00 Potential Upside/Downside+36.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.38% Return on Assets-37.88% Debt Debt-to-Equity Ratio0.72 Current Ratio8.61 Quick Ratio8.61 Sales & Book Value Annual Sales$460,000.00 Price / Sales4,660.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book12.75Miscellaneous Outstanding Shares81,240,000Free Float76,937,000Market Cap$2.14 billion OptionableOptionable Beta0.44 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. David S. Zaccardelli Pharm.D. (Age 60)President, CEO & Executive Director Comp: $1.27MMr. Mark W. Hahn (Age 61)Chief Financial Officer Comp: $858.29kDr. Kathleen A. Rickard M.D. (Age 66)Chief Medical Officer Comp: $650.83kMr. Andrew Fisher (Age 54)General Counsel Ms. Victoria StewartDirector of CommunicationsMr. Matthew CasbonVP of Sales, Marketing & TrainingMs. Ostra JewellSenior Vice President of Human ResourcesDr. Tara Rheault M.P.H. (Age 48)Ph.D., Chief Development Officer Mr. Christopher MartinChief Commercial OfficerMs. Caroline DiazSenior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsRoivant SciencesNASDAQ:ROIVAscendis Pharma A/SNASDAQ:ASNDIntra-Cellular TherapiesNASDAQ:ITCIElanco Animal HealthNYSE:ELANLantheusNASDAQ:LNTHView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCBought 150,210 shares on 8/27/2024Ownership: 0.508%Frazier Life Sciences Management L.P.Bought 300,000 shares on 8/16/2024Ownership: 4.101%Perceptive Advisors LLCSold 1,327,851 shares on 8/16/2024Ownership: 3.011%Quarry LPSold 3,500 shares on 8/16/2024Ownership: 0.002%Millennium Management LLCBought 23,567 shares on 8/15/2024Ownership: 0.653%View All Insider TransactionsView All Institutional Transactions VRNA Stock Analysis - Frequently Asked Questions How have VRNA shares performed this year? Verona Pharma's stock was trading at $19.88 at the start of the year. Since then, VRNA shares have increased by 32.7% and is now trading at $26.39. View the best growth stocks for 2024 here. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.53. When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Top institutional investors of Verona Pharma include NEA Management Company LLC (6.91%), Frazier Life Sciences Management L.P. (4.10%), Maverick Capital Ltd. (3.83%) and Perceptive Advisors LLC (3.01%). Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Martin Edwards and Lisa Deschamps. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR) and Inovio Pharmaceuticals (INO). This page (NASDAQ:VRNA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRNA Stock Alerts